Hopital Bretonneau

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Myeloproliferative neoplasms2 trials
• Colorectal cancer1 trial
• Cystic fibrosis1 trial
• High blood pressure1 trial
• Idiopathic pulmonary fibrosis1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Myelodysplastic syndromes1 trial
• Ovarian cancer1 trial
• Pulmonary arterial hypertension1 trial

Phase

• Phase 38 trials
• Phase 22 trials

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting3 trials
• Not yet recruiting2 trials
• Enrolling by invitation1 trial
• Suspended1 trial

Lead sponsor

• Assistance Publique - Hôpitaux de Paris2 trials
• Gustave Roussy, Cancer Campus, Grand Paris2 trials
• UNICANCER2 trials
• Groupe Francophone des Myelodysplasies1 trial
• Institut Cancerologie de l'Ouest1 trial
• and 5 more

Running trials

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

  Contact: Pascal MAGRO, PUPH

• Recruiting

  Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  NCT06475352· Phase 2· UNICANCER· Source

  Contact: Thierry LECOMTE, Pr. (principal investigator)

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Mathilde CANCEL, MD

• Recruiting

  Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)

  NCT05521776· Assistance Publique - Hôpitaux de Paris· Source

  Contact: Franck PERROTIN, Pr

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Active, not recruiting

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source

• Recruiting

  IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

  NCT05945576· Institut National de la Santé Et de la Recherche Médicale, France· Source

  Contact: Peggy PIERRE

• Active, not recruiting

  Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer

  NCT02089100· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Kidney cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Groupe Francophone des Myelodysplasies· Source

• Completed

  SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

  NCT02117167· Phase 2· UNICANCER· Source